1
|
Sera M, Yamashita M, Ono Y, Tabata T, Muto E, Ouchi T, Tawada H. Development of Large-Scale Synthesis using a Palladium-Catalyzed Cross-Coupling Reaction for an Isoquinolone Derivative as a Potent DPP-4 Inhibitor. Org Process Res Dev 2014. [DOI: 10.1021/op5000072] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Misayo Sera
- Chemical
Development Laboratories, CMC Center, Takeda Pharmaceutical
Company Limited, 17-85, Jusohonmachi
2-chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Makoto Yamashita
- Chemical
Development Laboratories, CMC Center, Takeda Pharmaceutical
Company Limited, 17-85, Jusohonmachi
2-chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Yuujirou Ono
- Chemical
Development Laboratories, CMC Center, Takeda Pharmaceutical
Company Limited, 17-85, Jusohonmachi
2-chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Takashi Tabata
- Chemical
Development Laboratories, CMC Center, Takeda Pharmaceutical
Company Limited, 17-85, Jusohonmachi
2-chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Eigo Muto
- Chemical
Development Laboratories, CMC Center, Takeda Pharmaceutical
Company Limited, 17-85, Jusohonmachi
2-chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Takashi Ouchi
- Chemical
Development Laboratories, CMC Center, Takeda Pharmaceutical
Company Limited, 17-85, Jusohonmachi
2-chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Hiroyuki Tawada
- Chemical
Development Laboratories, CMC Center, Takeda Pharmaceutical
Company Limited, 17-85, Jusohonmachi
2-chome, Yodogawa-ku, Osaka 532-8686, Japan
| |
Collapse
|
2
|
Shibata M, Nagai K, Usami K, Tawada H, Taniguchi S. The quantitative evaluation of online haemodiafiltration effect on skin hyperpigmentation. Nephrol Dial Transplant 2010; 26:988-92. [DOI: 10.1093/ndt/gfq479] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
3
|
Ikemoto T, Nishiguchi A, Ito T, Tawada H. Unusual asymmetric oxidation of sulfide; the diastereoselective oxidation of prochiral sulfide-chiral acid salt with hydrogen peroxide without metal. Tetrahedron 2005. [DOI: 10.1016/j.tet.2005.03.036] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
4
|
Ishikawa T, Matsunaga N, Tawada H, Kuroda N, Nakayama Y, Ishibashi Y, Tomimoto M, Ikeda Y, Tagawa Y, Iizawa Y, Okonogi K, Hashiguchi S, Miyake A. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003; 11:2427-37. [PMID: 12735989 DOI: 10.1016/s0968-0896(03)00126-3] [Citation(s) in RCA: 101] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Crystalline 1 (TAK-599) is a novel N-phosphono prodrug of anti-methicillin-resistant Staphylococcus aureus (MRSA) cephalosporin 2a (T-91825) that has high affinity for penicillin-binding protein (PBP) 2' (IC(50); 0.90 microg/mL) and shows potent in vitro anti-MRSA activity (MIC against MRSA N133; 1.56 microg/mL), comparable to that of vancomycin (1.56 microg/mL). Although 2a had insufficient water solubility (2.3 mg/mL) for parenteral administration, 1 showed excellent water solubility (>100 mg/mL, pH 7) as well as good chemical stability in the solid state and solution. In pharmacokinetic studies, when 1 was administered intravenously to rats and monkeys, it was rapidly converted into 2a in the blood. These results show that 1 (TAK-599) is a highly promising parenteral cephalosporin targeted for MRSA infection.
Collapse
Affiliation(s)
- Tomoyasu Ishikawa
- Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., 2-17-85 Jusohonmachi, Yodogawa-ku, 532-8686, Osaka, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Maekawa T, Sakai N, Tawada H, Murase K, Hazama M, Sugiyama Y, Momose Y. Synthesis and biological activity of novel 5-(omega-aryloxyalkyl)oxazole derivatives as brain-derived neurotrophic factor inducers. Chem Pharm Bull (Tokyo) 2003; 51:565-73. [PMID: 12736457 DOI: 10.1248/cpb.51.565] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A novel series of 5-(omega-aryloxyalkyl)oxazole derivatives was prepared and their effects on brain-derived neurotrophic factor (BDNF) production were evaluated in human neuroblastoma (SK-N-SH) cells. Syntheses were performed by construction of an oxazole ring as a key reaction. Most of the 5-(omega-aryloxyalkyl)oxazole derivatives markedly increased BDNF production in SK-N-SH cells. 4-(4-Chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-(2-methoxyphenoxy)propyl]-1, 3-oxazole, one of the most promising compounds, showed potent activity (EC(50)=7.9 microM) and the improvement of the motor nerve conduction velocity and the tail-flick response accompanied by a recovery of the brain-derived neurotrophic factor level in the sciatic nerve of streptozotocin (STZ)-diabetic rats.
Collapse
Affiliation(s)
- Tsuyoshi Maekawa
- Medicinal Chemistry Research Laboratories II, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, Japan.
| | | | | | | | | | | | | |
Collapse
|
6
|
Ishikawa T, Kamiyama K, Matsunaga N, Tawada H, Iizawa Y, Okonogi K, Miyake A. Studies on anti-MRSA parenteral cephalosporins. II. Synthesis and antibacterial activity of 7beta-[2-(5-amino-1,2,4- thiadiazol-3-yl)-2(Z)-alkoxyiminoacetamido]-3-(substituted imidaz. J Antibiot (Tokyo) 2000; 53:1071-85. [PMID: 11132951 DOI: 10.7164/antibiotics.53.1071] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
In an effort to discover a novel cefozopran (CZOP) derivative having excellent antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), we performed chemical modification of the alkoxyimino moiety and imidazo[1,2-b]pyridazinium group of CZOP. Among the prepared compounds, the cyclopentyloxyimino derivative 7beta-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-cyclopentyloxyiminoacetamido]-3-(3,6-diaminoimidazo[1,2-b]pyridazinium-1-yl)methyl-3-cephem-4-carboxylate (20 g) showed the most potent anti-MRSA activity, reflecting its high affinity (IC50 = 1.6 microg/ml) for penicillin binding protein 2' (PBP2'), although its anti-MRSA activity was slightly inferior to that of vancomycin (VCM). In experimental systemic infection in mice, however, 20 g showed activity comparable to that of VCM against MRSA. In addition, 20 g showed activity similar or slightly inferior to that of CZOP against Pseudomonas aeruginosa both in vitro and in vivo. Considering its favorable antibacterial activity profile, 20 g was considered to be the most promising CZOP derivative for further studies.
Collapse
Affiliation(s)
- T Ishikawa
- Pharmaceutical Research Division, Takeda Chemical Industries, Ltd, Osaka, Japan
| | | | | | | | | | | | | |
Collapse
|
7
|
Tawada H, Natsugari H, Ishikawa E, Sugiyama Y, Ikeda H, Meguro K. Synthesis of 3-ureido derivatives of coumarin and 2-quinolone as potent acyl-CoA: cholesterol acyltransferase inhibitors. Chem Pharm Bull (Tokyo) 1995; 43:616-25. [PMID: 7600615 DOI: 10.1248/cpb.43.616] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Novel 3-ureido derivatives of 4-phenylcoumarin and 4-phenyl-2-quinolone were synthesized and evaluated for acyl-CoA: cholesterol acyltransferase (ACAT)-inhibitory activity. These derivatives inhibited rat intestinal ACAT with IC50 values at the 10(-8) to 10(-9) M level and were found to normalize plasma cholesterol levels in cholesterol-fed rats when administered as dietary admixtures.
Collapse
Affiliation(s)
- H Tawada
- Pharmaceutical Research Laboratories II, Takeda Chemical Industries, Ltd., Osaka, Japan
| | | | | | | | | | | |
Collapse
|
8
|
Sugiyama Y, Ishikawa E, Odaka H, Miki N, Tawada H, Ikeda H. TMP-153, a novel ACAT inhibitor, inhibits cholesterol absorption and lowers plasma cholesterol in rats and hamsters. Atherosclerosis 1995; 113:71-8. [PMID: 7755657 DOI: 10.1016/0021-9150(94)05429-m] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Effects of TMP-153, N-[4-(2-chlorophenyl)-6,7-dimethyl-3-quinolyl]-N'-(2,4-difluorophe nyl)urea, on intestinal and hepatic acyl-CoA:cholesterol acyltransferase (ACAT) activities, cholesterol absorption and plasma cholesterol level in rats and hamsters were studied. TMP-153 has IC50 values of around 5-10 nM for the hepatic and intestinal ACAT from various animals. The most potent inhibition was observed in the intestinal ACAT from Golden hamsters (IC50 = 2.3 nM). The inhibition mode of TMP-153 was non-competitive for rat intestinal ACAT. TMP-153 inhibited cholesterol esterification both in human colonic adenocarcinoma cells, LS180, and in human hepatoma cells, HepG2 (IC50 = 150 nM and 330 nM, respectively). [14C]cholesterol and cold cholesterol absorption from the small intestine was markedly inhibited by oral administration of TMP-153 (1 mg/kg) without affecting lymph flow and triglyceride absorption. When the compound was given as a dietary admixture, plasma cholesterol was reduced in rats fed a cholesterol diet (ED50 = 0.25 mg/kg/day), but not in those fed a stock diet. On the other hand, TMP-153 showed more prominent hypocholesterolemic effect in Golden hamsters fed the stock diet (ED50 = 0.81 mg/kg/day) than in those fed the cholesterol diet (ED50 = 8.01 mg/kg/day). In hamsters fed the stock diet, TMP-153 markedly decreased the hepatic unesterified cholesterol in addition to esterified cholesterol content, but did not affect bile flow and the biliary secretion of bile acid and lipids. Different mechanisms for plasma cholesterol lowering by TMP-153 between rats and hamsters was discussed.
Collapse
Affiliation(s)
- Y Sugiyama
- Pharmaceutical Research Laboratories II, Takeda Chemical Industries, Ltd., Osaka, Japan
| | | | | | | | | | | |
Collapse
|
9
|
Tawada H, Harcourt M, Kawamura N, Kajino M, Ishikawa E, Sugiyama Y, Ikeda H, Meguro K. Novel acyl-CoA:cholesterol acyltransferase inhibitors. Synthesis and biological activity of 3-quinolylurea derivatives. J Med Chem 1994; 37:2079-84. [PMID: 8027989 DOI: 10.1021/jm00039a020] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
A series of 3-quinolylurea derivatives (1) was synthesized and evaluated for acyl-CoA:cholesterol acyltransferase (ACAT) inhibitory activity. For in vitro studies, the most potent inhibitory activity was found in derivatives having substituents at the 6,7- or 6,8-positions and an ortho-substituted phenyl group at the 4-position of quinoline ring. The 2,4-difluorophenyl group appeared to be the optimum N'-substituent of the urea moiety. The IC50 values of compounds 52-54 and 59 were in the nanomolar order. Plasma cholesterol-lowering activity of compounds 50, 52, and 54 was observed at less than 1 mg/kg/day in cholesterol-fed rats. Compound 52 was also hypocholesterolemic in hamsters fed a diet without loading cholesterol.
Collapse
Affiliation(s)
- H Tawada
- Pharmaceutical Research Laboratories II, Takeda Chemical Industries, Ltd., Osaka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Kajino M, Mizuno K, Tawada H, Shibouta Y, Nishikawa K, Meguro K. Synthesis and biological activities of new 1,4-benzothiazine derivatives. Chem Pharm Bull (Tokyo) 1991; 39:2888-95. [PMID: 1799937 DOI: 10.1248/cpb.39.2888] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
New 2H-1,4-benzothiazin-3(4H)-one derivatives possessing (4-phenyl-1-piperazinyl)alkyl moieties at the 2-position were synthesized and tested for calcium antagonistic and calmodulin antagonistic activities. Antihypertensive effects in spontaneously hypertensive rats were also evaluated. In general, these compounds were rather weak calcium channel blockers, although, in contrast, many of them had moderate to potent calmodulin antagonistic activity, and 2-[3-(4-(4-fluorophenyl)-1-piperazinyl]propyl]-2H-1,4-benzothiazin -3 (4H)-one derivatives 45, 74 and 75 showed potent antihypertensive effects.
Collapse
Affiliation(s)
- M Kajino
- Chemistry Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, Japan
| | | | | | | | | | | |
Collapse
|
11
|
Tawada H, Sugiyama Y, Ikeda H, Yamamoto Y, Meguro K. Studies on antidiabetic agents. IX. A new aldose reductase inhibitor, AD-5467, and related 1,4-benzoxazine and 1,4-benzothiazine derivatives: synthesis and biological activity. Chem Pharm Bull (Tokyo) 1990; 38:1238-45. [PMID: 2118427 DOI: 10.1248/cpb.38.1238] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
N-Acetic acid derivatives (I) of 2-substituted 1,4-benzoxazines and benzothiazines were designed and synthesized for evaluation as new aldose reductase inhibitors. In general, 3-thioxo derivatives were more potent inhibitors of aldose reductase from human palcenta in vitro than the corresponding 3-oxo derivatives. While many compounds (I) were not very effective in inhibiting sorbitol accumulation in the rat sciatic nerve in vivo, the 3-thioxo compounds bearing an isopropyl group at the 2-position showed highly potent activity in the in vivo assay. Compound 46 (AD-5467) was selected from this series as a candidate for further development.
Collapse
Affiliation(s)
- H Tawada
- Chemistry Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, Japan
| | | | | | | | | |
Collapse
|
12
|
Sugiyama Y, Taketomi S, Tawada H, Meguro K, Ikeda H, Fujita T. Selective potentiation of 5-methyl-2-(1-methylcyclohexyl)-4-oxazoleacetic acid (AD-4610) on glucose-induced insulin secretion. Horm Metab Res 1988; 20:145-9. [PMID: 3290076 DOI: 10.1055/s-2007-1010779] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
In the perfused pancreas from normal SD rats, AD-4610 (0.01-0.1 mM) potentiated biphasic insulin secretion induced by 7.5 mM of glucose. The concentration-response curve of insulin secretion to glucose was shifted leftwards with AD-4610 (0.1 mM) without altering either the threshold concentration of glucose to induce insulin secretion or the maximal insulin response to glucose, indicating increased sensitivity of the pancreatic B-cells to glucose. On the other hand, AD-4610 was 10-fold less effective in altering insulin secretion induced by arginine and glyceraldehyde. The effect of AD-4610 on insulin secretion and glucose metabolism was compared with that of tolbutamide in vivo. AD-4610 (100 mg/kg) potentiated insulin secretion induced by an intravenous glucose load, and also accelerated glucose metabolism without altering basal insulin secretion in normal rats. On the other hand, tolbutamide (20 mg/kg) increased basal insulin secretion, but slightly decreased glucose-induced insulin secretion. In yellow KK mice with hyperglycemia, AD-4610 (10-100 mg/kg) had a dose-dependent hypoglycemic action, but tolbutamide did not. Thus, AD-4610 stimulated insulin secretion in a glucose-dependent fashion and enhanced glucose metabolism in vivo. These results suggest that AD-4610 selectively potentiates glucose-induced insulin secretion by increasing the sensitivity of pancreatic B-cells to glucose and may be useful for treating human NIDDM through a different mechanism than that of tolbutamide.
Collapse
Affiliation(s)
- Y Sugiyama
- Biology Laboratory, Takeda Chemical Industries, Ltd., Osaka, Japan
| | | | | | | | | | | |
Collapse
|
13
|
Meguro K, Tawada H, Sugiyama Y, Fujita T, Kawamatsu Y. Studies on antidiabetic agents. VII. Synthesis and hypoglycemic activity of 4-oxazoleacetic acid derivatives. Chem Pharm Bull (Tokyo) 1986; 34:2840-51. [PMID: 3769086 DOI: 10.1248/cpb.34.2840] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
14
|
Tawada H, Okura T, Watanabe Y, Fukatsu A, Ishiguro T, Oshida Y, Sakamoto N. [Clinicopathologic study of IgA nephropathy and non-IgA mesangial proliferative glomerulonephritis]. Nihon Jinzo Gakkai Shi 1985; 27:1503-14. [PMID: 3831468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
15
|
Okura T, Tawada H, Matsuo S, Sato Y, Miyauchi J, Ando I, Oshida Y, Ishiguro T, Sakamoto N. [Urinary enzyme excretion in nephropathia--with special reference to chance proteinuria and/or hematuria]. Nihon Jinzo Gakkai Shi 1984; 26:791-803. [PMID: 6151009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
16
|
Tamaki S, Okura T, Watanabe Y, Tawada H, Matsuo S, Ando I, Sato Y, Sakamoto N. [Histopathological study of isolated hematuria]. Nihon Jinzo Gakkai Shi 1983; 25:1217-32. [PMID: 6674644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
17
|
Sohda T, Mizuno K, Tawada H, Sugiyama Y, Fujita T, Kawamatsu Y. Studies on antidiabetic agents. I. Synthesis of 5-[4-(2-methyl-2-phenylpropoxy)-benzyl]thiazolidine-2,4-dione (AL-321) and related compounds. Chem Pharm Bull (Tokyo) 1982; 30:3563-73. [PMID: 7160011 DOI: 10.1248/cpb.30.3563] [Citation(s) in RCA: 67] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
18
|
Sohda T, Mizuno K, Imamiya E, Tawada H, Meguro K, Kawamatsu Y, Yamamoto Y. Studies on antidiabetic agents. III. 5-Arylthiazolidine-2,4-diones as potent aldose reductase inhibitors. Chem Pharm Bull (Tokyo) 1982; 30:3601-16. [PMID: 6819094 DOI: 10.1248/cpb.30.3601] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
19
|
Meguro K, Tawada H, Kuwada Y. [Heterocycles. II. A new method for the preparation of 2-amino- and 2-imino-1,4-benzodiazepines (author's transl)]. YAKUGAKU ZASSHI 1973; 93:1253-62. [PMID: 4798499 DOI: 10.1248/yakushi1947.93.10_1253] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|